Alzheimer’s Disease Diagnostic Market
Alzheimer’s Disease Diagnostic Market Scope:
Industry Analysis, Market Size, Growth, Trends Till
2031
Request Sample Report
Alzheimer’s Disease Diagnostic Market Size and Growth
The global Alzheimer's Disease Diagnostic market is projected to reach $5.6 billion by 2025, driven by increasing prevalence of the disease and rising demand for early detection tools. Technological advancements and government initiatives are also contributing to market growth. Key players in the market include GE Healthcare, Siemens Healthineers, and Roche Diagnostics.
Companies Covered
(Covid 19 Impact Covered)
◍ Eli Lilly and Company
◍ Novartis
◍ Merck
◍ F. Hoffmann-La Roche
◍ Pfizer
◍ TauRx
◍ Alector
◍ Accera
◍ Treventis Corporation
◍ Neuro-Bio
◍ Cognition Therapeutics
The competitive landscape of the Alzheimer's Disease Diagnostic Market includes key players such as Eli Lilly and Company, Novartis, Merck, F. Hoffmann-La Roche, Pfizer, TauRx, Alector, Accera, Treventis Corporation, Neuro-Bio, and Cognition Therapeutics. These companies develop diagnostic tools and therapies to improve early detection and treatment of Alzheimer's Disease, contributing to the growth of the market.
- Eli Lilly and Company: $24.6 billion
- Novartis: $47.5 billion
- Merck: $46.8 billion
Market Segmentation
By Application
◍ Familial Alzheimer's Disease
◍ Late-Onset Alzheimer's Disease
By
Product
Brain Imaging ◍ Early-Onset Alzheimer's Disease
◍ Nervous System Examination
Genetic Testing
Minor Mental State Examination (Mmse)
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
